Novel Molecular Imaging of Atherosclerosis With Gallium-68-Labeled Apolipoprotein A-I Mimetic Peptide and Positron Emission Tomography

• Kawachi Emi

  Department of Cardiology, Fukuoka University School of Medicine

• Uehara Yoshinari

  Department of Cardiology, Fukuoka University School of Medicine

• Hasegawa Koki

  RIKEN Center for Molecular Imaging Science

• Yahiro Eiji

  Department of Cardiology, Fukuoka University School of Medicine Department of Community and Emergency Medicine, Fukuoka University

• Ando Setsuko

  Department of Chemistry, Faculty of Science, Fukuoka University

• Wada Yasuhiro

  RIKEN Center for Molecular Imaging Science

• Yano Tsuneo

  RIKEN Center for Molecular Imaging Science

• Nishikawa Hiroaki

  Department of Cardiology, Fukuoka University School of Medicine

• Shiomi Masashi

  Institute for Experimental Animals, Kobe University Graduate School of Medicine

• Miura Shin-ichiro

  Department of Cardiology, Fukuoka University School of Medicine

• Watanabe Yasuyoshi

  RIKEN Center for Molecular Imaging Science

• Saku Keijiro

  Department of Cardiology, Fukuoka University School of Medicine

Bibliographic Information

Other Title

• Novel molecular imaging of atherosclerosis with 68Ga-labeled apo A-I mimetic peptide and positron emission tomography

Abstract

Background: High-density lipoprotein (HDL) plays a major role in reverse cholesterol transport. Many researchers have been working to enhance the biochemical function of HDL for use in therapy. Although HDL therapy using injections of apolipoprotein (apo)-A-I mimetics, apo A-I _Milano or full-length apo A-I is dramatically effective, it is still unclear whether apo A-I or apo A-I mimetics actually enter atherosclerotic plaque and remove cholesterol from the lipid burden. We synthesized a novel 24-amino acid apo A-I mimetic peptide (known as FAMP) that potently removes cholesterol via specific ATP-binding cassette transporter A1. We then investigated the potential of FAMP to image developing plaque lesions in vivo. Methods and Results: FAMP was modified with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and radiolabeled with gallium-68 (⁶⁸Ga) for noninvasive positron emission tomography (PET) in an animal model (familial hypercholesterolemic myocardial infarction-prone rabbits: WHHL-MI) with atherosclerotic lesions. The ⁶⁸Ga-DOTA-FAMP was dramatically taken up by atherosclerotic tissues in the blood vessels and aorta of WHHL-MI rabbits, but not the control rabbits. Conclusions: An apo A-I mimetic peptide with ⁶⁸Ga-DOTA is a promising candidate diagnostic tracer for PET imaging of the atherosclerotic lipid burden and may contribute to the development of a tool for the diagnosis of plaque with PET.  (Circ J 2013; 77: 1482–1489)<br>

Journal

• Circulation Journal

  Circulation Journal 77 (6), 1482-1489, 2013

  The Japanese Circulation Society

Keywords

• Apo A-I mimetic peptide
• Atherosclerosis
• High-density lipoprotein
• PET imaging
• Plaque

Details

• CRID: 1390282680079344000
• NII Article ID: 10031158878
• NII Article ID: 130003361654
• NII Book ID: AA11591968
• DOI: 10.1253/circj.cj-12-0736
• COI: 1:CAS:528:DC%2BC3sXpvVaqtrk%3D
• ISSN: 13474820
• ISSN: 13469843
• PubMed: 23459406
• Web Site: https://www.jstage.jst.go.jp/article/circj/77/6/77_CJ-12-0736/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2014145478
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed